Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
Abetimus (LJP 394 free base) administration is considered to lower the amount of anti-dsDNA Abs in circulation through at least two ways. Initially, Abetimus (LJP 394 free base) rapidly reduces the amount of anti-dsDNA antibodies in circulation, most likely through the formation of tiny, soluble complexes that don't seem to significantly activate the complement system. Second, B cells are bound by Abetimus (LJP 394 free base) without T-cell activation, which causes B cells to undergo apoptosis and decreases the production of anti-dsDNA antibodies. Actually, it appears that Abetimus (LJP 394 free base) induces B-cell tolerance by activating the signal transduction pathways that result in B-cell death or anergy via crosslinking anti-dsDNA surface immunoglobulin receptors on B cells[1].
|
---|---|
ln Vivo |
In male BXSB mice, a model for systemic lupus, abelimus (LJP 394 free base) is efficient in decreasing anti-dsDNA-mediated diseases. Beginning at around nine weeks of age, mice given two weekly intravenous doses of Abetimus (3-300 μg/mouse) exhibit considerably lower anti-dsDNA titers, fewer anti-dsDNA-secreting spleen cells, and less detrimental renal histopathology as compared to control mice[2]. In mice, the pharmacokinetic half-life of abetimus ranges from 40 minutes to one hour[1].
|
References |
[1]. Marta Mosca, et al. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother. 2007 Apr;8(6):873-9.
[2]. S M Coutts, et al. Pharmacological intervention in antibody mediated disease. Lupus. 1996 Apr;5(2):158-9. |
Molecular Formula |
C1632H2100N610O97P156S4
|
---|---|
Molecular Weight |
50742.05
|
CAS # |
167362-48-3
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.0197 mL | 0.0985 mL | 0.1971 mL | |
5 mM | 0.0039 mL | 0.0197 mL | 0.0394 mL | |
10 mM | 0.0020 mL | 0.0099 mL | 0.0197 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.